If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 101 - 110 of 275
REMASTer: REcurrent Brain Metastases After SRS Trial
Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer,
Endocrine Cancers,
Uterine,
Other Urologic,
Colorectal,
Cervix,
Lung,
Brain and Spine Cancers,
Prostate,
Stomach,
Skin Cancers,
Prostate and Urologic Cancers,
Other Respiratory,
Gastrointestinal Cancers,
Breast Cancers,
Head and Neck Cancers,
Esophagus,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Gynecologic Cancers,
Sarcoma,
Eye/Orbital Cancers
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive fo
Objective
A Phase1 Study of NT-112 in Patients with Advanced Solid Tumors Positive for KRAS G12D Mutation
Protocol No
NEOGENE-NT-112-301
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Objective
A Phase 2 Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis
Protocol No
NMDP-CIBMTR-OPTIMIZE
Categories
Phase 1/2 Study of REGN4336 (a PSMAxCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN5678 (a PSMAxCD28 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer
Objective
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
The Effect of Intraoperative Brain Stimulation on Hand Strength and Function During Awake Craniotomies
Objective
Intraoperative Hand Function
Protocol No
IIT-KRUCOFF-INTRAOP-HAND-FUNC
Categories
Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery
Objective
Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery
Protocol No
IIT-ZENGA-SSI-OCR
Categories
A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung
Objective
Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Protocol No
INF-AN2-EBO-301-MAC
Categories
Expanded Access IND Protocol: Use of Tecovirimat (TPOXX) for Treatment of Human Orthopoxvirus Infections (CDC IND 116039, CDC IRB Protocol #6402)
Objective
TPOXX for Treatment of Human Orthopoxvirus Infections
Protocol No
INF-CDC-TPOXX-EA-IND-MONKEYPOX
Categories
A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of Care in Vi
Objective
HIV Embrace
Protocol No
INF-GSK-EMBRACE-HIV
Categories
A Multicenter, Adaptive, Randomized, Controlled, Trial Platform to Evaluate Safety and Efficacy Strategies and Treatments for Hospitalized Patients with Respiratory Infections
Objective
Safety, Efficacy and Tx Strategies for Hospitalized Patients with Respiratory Infections
Protocol No
INF-NIAID-STRIVE
Categories